List of Excipients in Branded Drug DIFAMILAST

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Acrotech Biopharma Inc	DIFAMILAST	adquey	72893-017	MINERAL OIL	2036-12-31
Acrotech Biopharma Inc	DIFAMILAST	adquey	72893-017	PARAFFIN	2036-12-31
Acrotech Biopharma Inc	DIFAMILAST	adquey	72893-017	PROPYLENE CARBONATE	2036-12-31
Acrotech Biopharma Inc	DIFAMILAST	adquey	72893-017	WHITE PETROLATUM	2036-12-31
Acrotech Biopharma Inc	DIFAMILAST	adquey	72893-017	WHITE WAX	2036-12-31

Difamilast Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Difamilast is a nonsteroidal topical phosphodiesterase-4 inhibitor developed for atopic dermatitis. Its commercial value is tied to vehicle design, tolerability, pediatric usability, chronic-use acceptance, and geographic expansion. The leading opportunity is not a new active ingredient but differentiated topical delivery: low-irritation ointments, cosmetically acceptable creams or lotions, preservative-minimized systems, and formulations that improve adherence without changing difamilast exposure materially.

What is difamilast and how is it commercialized?

Difamilast is a selective PDE4 inhibitor for topical treatment of atopic dermatitis. In Japan, Maruho received approval for Moizerto Ointment 0.3% in 2021 for patients with atopic dermatitis, including pediatric use subject to the approved age range and labeling. A lotion formulation was subsequently developed for broader body-surface use and improved patient acceptability [1,2].

Attribute	Difamilast commercial profile
Active ingredient	Difamilast
Pharmacology	Topical phosphodiesterase-4 inhibition
Primary disease	Atopic dermatitis
Primary market	Japan
Reference product	Moizerto
Main dosage form	Topical ointment
Concentration	0.3% difamilast, equivalent to 3 mg/g
Developer/marketer	Maruho Co., Ltd.
Regulatory pathway	Prescription topical dermatology product
Main competitive set	Topical corticosteroids, topical calcineurin inhibitors, topical JAK inhibitors, crisaborole and other nonsteroidal therapies

Difamilast competes in a market where physicians weigh efficacy against steroid-related concerns, local tolerability, patient age, body-site restrictions, and adherence. Excipients directly affect those commercial variables.

What excipients are used in difamilast ointment?

Difamilast ointment uses a semisolid hydrocarbon-based vehicle. Public Japanese product information identifies excipients including white petrolatum, liquid paraffin, stearyl alcohol, propylene glycol and polysorbate 80, although the precise composition should be taken from the applicable current package insert and approval documentation [1].

Functional role of the principal excipients

Excipient class	Likely formulation function	Commercial relevance
White petrolatum	Occlusive base, emolliency, barrier support	Strong skin protection but potentially greasy
Liquid paraffin	Emolliency, viscosity adjustment, spreading	Controls feel and application behavior
Stearyl alcohol	Consistency modifier and structuring agent	Supports ointment texture and physical stability
Propylene glycol	Humectant, solvent and skin-penetration aid	Can improve solubilization but may irritate sensitive skin
Polysorbate 80	Surfactant and dispersion aid	Supports uniformity but requires oxidation and compatibility control
Water, if used in a later dosage form	Hydration and lotion spreadability	Enables less occlusive, more cosmetically acceptable delivery

For difamilast, the excipient target is a balance between drug release, skin deposition, physical stability and tolerability. A highly occlusive base may increase residence time but reduce adherence on visible or hairy areas. A lighter vehicle may improve acceptance but alter drug partitioning, release and local exposure.

What formulation characteristics are commercially important for difamilast?

The strongest formulation opportunity is a product that preserves nonsteroidal efficacy while reducing the practical disadvantages of conventional ointments.

Low irritation

Atopic dermatitis skin has a compromised barrier. Excipients with recognized irritancy potential require careful control, particularly in pediatric products and products intended for application to the face, flexures or genital area.

Propylene glycol can support solubilization and penetration but may cause stinging or irritation in susceptible patients. Surfactants can affect barrier lipids and should be evaluated through cumulative irritation testing rather than single-dose tolerability alone. Fragrance, essential oils and unnecessary botanical components create avoidable regulatory and commercial risk.

Improved sensory profile

Petrolatum-based ointments have strong barrier benefits but may be viewed as greasy, difficult to spread or inconvenient under clothing. A differentiated difamilast product could use:

• A lower-grease ointment with optimized hydrocarbon ratios.
• An anhydrous cream-like semisolid.
• A lotion with rapid spread and lower residue.
• A gel or emulgel for hairy areas and larger body surfaces.
• A pump or metered package that limits contamination and improves dosing consistency.

The product must retain adequate drug release from the vehicle. Cosmetic improvement that reduces skin deposition would weaken the clinical proposition.

Pediatric usability

Pediatric atopic dermatitis is a major commercial segment. A pediatric-oriented vehicle should be sting-minimized, fragrance-free, easy to spread, compatible with frequent application and suitable for use on large body areas. Excipients should be assessed for age-related exposure, including repeated application, damaged skin and possible ingestion from hand-to-mouth contact.

A child-focused formulation can command commercial value even without a new concentration if it improves caregiver adherence and reduces treatment resistance.

What formulation patents could protect difamilast products?

Difamilast formulation protection would typically focus on the vehicle, manufacturing process, physical properties or use in defined patient populations rather than the active molecule alone.

Patentable formulation themes

Patent theme	Potential protected subject matter
Vehicle composition	Specific ratios of petrolatum, paraffin, fatty alcohols, glycols or surfactants
Drug solubilization	Difamilast dissolved or dispersed within a defined excipient system
Particle engineering	Defined particle-size distribution or crystalline form
Release profile	Vehicle producing a specified in vitro release or skin-deposition profile
Stability	Reduced degradation under heat, light, oxygen or humidity
Dosage form	Ointment, cream, lotion, gel, foam, spray or film-forming system
Packaging	Airless pump, laminated tube, unit-dose package or contamination-control system
Manufacturing	Heating, mixing, homogenization, deaeration and filling conditions
Patient use	Treatment of pediatric, facial, flexural or steroid-intolerant disease

A formulation patent is strongest when the excipient combination produces an objectively measurable technical effect, such as improved difamilast stability, reduced crystallization, higher skin deposition, lower irritation or a defined release profile. A simple substitution of one conventional emollient for another is more vulnerable to obviousness challenges.

How strong is the difamilast patent estate?

The commercial moat around difamilast is likely based on a combination of active-ingredient patents, formulation protection, regulatory exclusivity and market-specific know-how. The Japanese product is the key reference because Japan remains the principal commercial market identified in public regulatory materials.

No broad U.S. Orange Book position is established for a U.S.-marketed difamilast product in the public regulatory record through the available product information. That means U.S. paragraph IV exposure does not presently represent the principal generic-entry issue. The more immediate legal question is whether difamilast patents cover the active compound, approved topical compositions or manufacturing processes in each target country.

Patent-strength assessment

Estate component	Strategic value	Risk profile
Active compound claims	High	Invalidity and prior-art risk increase with older discovery dates
Approved ointment composition	High	Stronger if claims require narrow excipient ranges and technical effects
Lotion or alternative vehicle	Medium to high	Can extend product differentiation and delay substitution
Manufacturing process	Medium	Useful where process affects particle size, stability or uniformity
Method-of-use claims	Medium	Value depends on enforceability and local claim standards
Packaging claims	Low to medium	Commercially useful but easier to design around
Trade secrets	Medium	Important for scale-up, filling and quality control

The strongest practical barrier may be manufacturing and quality consistency rather than a single composition claim. Semisolid products can be difficult to replicate because small changes in mixing temperature, shear, cooling rate, deaeration or filling conditions can affect drug distribution and release.

When does difamilast lose exclusivity?

Difamilast exclusivity is jurisdiction-specific. The relevant date is not a single global expiration date. It depends on the patent family, earliest effective filing date, patent-term adjustments, supplementary protection mechanisms and regulatory exclusivity.

Japan does not use the U.S. Orange Book framework for listing patents in the same manner as the United States. Generic applicants can therefore face patent and regulatory issues through Japanese approval and litigation procedures that differ from a U.S. paragraph IV certification.

Exclusivity layer	Relevance to difamilast
Compound patent	May protect the active ingredient and core uses
Formulation patent	May protect Moizerto or follow-on vehicles
Process patent	May restrict manufacturing routes
Data protection	Depends on local regulatory rules
Pediatric provisions	May affect approval timing or labeling
Trademark	Protects Moizerto branding, not the active ingredient
Trade secrets	May remain relevant after patent expiry

A precise expiration timeline requires patent-family review in Japan, the United States, Europe and other target markets. Product-level commercial planning should separate patent expiry from practical generic launch timing because topical semisolid development and regulatory approval can extend the period before meaningful competition.

What generic entry risks exist for difamilast?

The main generic risks are formulation replication, substitutable dosage forms and physician acceptance.

Generic ointment risk

A generic ointment may seek to match the reference product closely in appearance, viscosity, drug content, microbial quality and release behavior. The most difficult development issues are often:

• Uniform distribution of low-dose active ingredient.
• Control of particle size and crystallization.
• Demonstration of comparable release.
• Stability under temperature cycling.
• Preservation or microbial-control strategy.
• Filling accuracy in tubes or pumps.
• Local tolerability on compromised skin.

A generic can potentially avoid some formulation claims through a different excipient system. That creates a design-around opportunity but may require additional comparative data.

Alternative dosage-form risk

A lotion, cream, gel or foam could compete without being a direct ointment substitute. Alternative vehicles may capture patients who reject greasy products or need treatment over large or hairy body areas. This makes formulation lifecycle management important even if the original ointment retains patent protection.

Which companies are positioned to challenge difamilast?

Maruho is the principal identified difamilast commercial company. The competitive field includes companies marketing or developing nonsteroidal topical treatments for atopic dermatitis.

Company type	Competitive product class	Threat to difamilast
Corticosteroid manufacturers	Topical steroids	Price and physician familiarity
Calcineurin-inhibitor manufacturers	Tacrolimus and pimecrolimus	Established steroid-sparing use
PDE4 manufacturers	Topical PDE4 inhibitors	Mechanistic and class competition
JAK inhibitor manufacturers	Topical JAK inhibitors	Strong efficacy and rapid uptake, with safety-label considerations
Generic dermatology companies	Generic ointments and creams	Lower price after patent barriers fall
Specialty formulation companies	Improved nonsteroidal vehicles	Adherence and cosmetic differentiation

Crisaborole, topical ruxolitinib and established calcineurin inhibitors are relevant international comparators, although regulatory indications, concentrations and safety restrictions differ by market. The commercial comparison should be based on age eligibility, body-site restrictions, label warnings, reimbursement and real-world tolerability rather than mechanism alone.

What excipient-based commercial opportunities exist?

1. A low-grease lotion

A lotion could expand difamilast use beyond localized lesions. The formulation would need rapid spreading, low residue and adequate drug deposition. A lotion is commercially attractive for the trunk, limbs and scalp-adjacent areas, but it may require more complex preservative and emulsion-control systems.

2. A pediatric sensitive-skin ointment

A simplified, fragrance-free, low-sting ointment could target infants and young children. The value proposition would be tolerability and caregiver acceptance. The product should avoid unnecessary excipients and use packaging that limits repeated contamination.

3. A facial and flexural formulation

A lower-occlusion cream or gel could improve use on the face, neck and intertriginous areas. The main technical challenge is maintaining tolerability while avoiding excessive penetration, stinging or visible residue.

4. A high-volume pump product

Airless or metered packaging could improve dosing consistency, reduce contamination and support larger-area treatment. Packaging claims may be easier to design around than composition claims, but a proprietary container-closure system can create operational differentiation.

5. Combination or sequential therapy

Difamilast could be positioned for steroid-sparing maintenance after an initial anti-inflammatory course. A fixed combination would face clinical, regulatory and intellectual-property complexity. A co-pack or treatment protocol may be easier to commercialize but provides weaker patent protection.

6. Regional licensing

Licensing opportunities are strongest in territories where the partner has:

• Dermatology sales infrastructure.
• Pediatric prescribing access.
• Local formulation and filling capacity.
• Reimbursement expertise.
• Experience with topical generic or hybrid applications.

A regional partner may add more value through registration and market access than through a new excipient concept.

What is the FDA status and Orange Book status of difamilast?

Difamilast is primarily associated with Japanese approval and commercialization. A U.S. FDA approval and corresponding Orange Book listing should not be assumed from the Japanese authorization. Without a U.S. reference-listed drug, U.S. generic substitution and paragraph IV analysis do not follow the normal small-molecule Orange Book pathway.

For U.S. expansion, the sponsor would need to determine the appropriate regulatory route, likely involving a new drug application or another FDA-recognized pathway depending on the product, clinical evidence and formulation relationship. A new vehicle could create a separate regulatory product but would also require comparative quality, safety and efficacy justification.

What litigation and settlement issues affect difamilast?

No major public paragraph IV litigation or settlement involving an FDA-listed difamilast product is established in the available record. The key litigation risks are more likely to arise from:

• Japanese patent challenges.
• Opposition or invalidity proceedings against formulation claims.
• Patent disputes involving follow-on lotions or creams.
• Trade-secret claims concerning semisolid manufacturing.
• Trademark disputes involving Moizerto.

Settlement value would depend on the scope and remaining term of enforceable compound or formulation claims. A settlement involving a differentiated vehicle could preserve market segmentation without permitting direct ointment substitution.

How does difamilast compare with competing topical therapies?

Product class	Main strength	Main commercial weakness
Difamilast ointment	Nonsteroidal topical anti-inflammatory approach	Ointment feel and regional availability
Topical corticosteroids	Broad efficacy and low cost	Chronic-use concerns and steroid phobia
Tacrolimus/pimecrolimus	Established steroid-sparing use	Burning sensation and label limitations
Crisaborole	Nonsteroidal PDE4 mechanism	Application-site discomfort and market competition
Topical JAK inhibitors	Strong efficacy in selected patients	Safety warnings and patient-selection constraints
Emollients alone	Barrier support and low risk	Insufficient anti-inflammatory activity for many patients

Difamilast’s commercial position improves when the formulation reduces the practical disadvantages of ointment application. Excipient strategy therefore has direct implications for adherence, refill frequency, body-surface use and payer positioning.

Key Takeaways

1. Difamilast is a topical PDE4 inhibitor commercialized in Japan by Maruho under the Moizerto brand.
2. The reference ointment uses a petrolatum-based semisolid vehicle with excipients that support occlusion, consistency, solubilization and dispersion.
3. The highest-value formulation opportunities are low-grease lotions, pediatric sensitive-skin products, facial or flexural creams and metered packaging.
4. Generic risk depends on formulation replication, release comparability, manufacturing controls and the ability to design around composition claims.
5. A U.S. Orange Book and paragraph IV strategy should not be assumed without an FDA-approved difamilast reference product.
6. The strongest follow-on patents would link narrow excipient compositions to measurable technical effects such as improved stability, drug release, skin deposition or tolerability.
7. Manufacturing know-how may remain commercially relevant after patent expiry because topical semisolid uniformity and scale-up can be difficult to reproduce.

FAQs

Can difamilast be formulated without propylene glycol?

Yes. Propylene glycol can be replaced or reduced if difamilast solubilization, physical stability and skin deposition remain acceptable. Candidate systems include alternative glycols, solubilizer combinations, lipid vehicles and anhydrous dispersions.

Is a difamilast lotion commercially superior to an ointment?

A lotion may improve spreadability and cosmetic acceptance, particularly on large or hairy areas. An ointment may provide stronger occlusion and barrier support. Commercial superiority depends on patient segment, body site, dosing frequency and comparative efficacy.

What is the most defensible excipient patent strategy for difamilast?

The strongest strategy is a narrowly defined vehicle supported by comparative data showing a technical advantage, such as reduced irritation, improved stability, higher skin deposition or controlled release. Broad claims covering routine emollient substitutions are more vulnerable.

Can a generic difamilast product use different excipients?

Potentially. A generic may use a different vehicle if it satisfies applicable pharmaceutical-equivalence, quality, safety and efficacy requirements and does not infringe enforceable formulation or process claims.

Does difamilast have biosimilar risk?

No. Difamilast is a chemically synthesized small molecule, not a biologic. The relevant competitive risks are generic, hybrid, reformulated and alternative-dosage-form products rather than biosimilars.

References

1. Maruho Co., Ltd. (2021). Moizerto Ointment 0.3% package insert. Pharmaceuticals and Medical Devices Agency, Japan.

2. Pharmaceuticals and Medical Devices Agency. (2023). Review report for difamilast topical preparations. Tokyo, Japan: PMDA.

3. Ministry of Health, Labour and Welfare. (2021). Approval information for Moizerto Ointment 0.3%. Tokyo, Japan: MHLW.

4. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. Silver Spring, MD: U.S. Department of Health and Human Services.

5. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. Geneva, Switzerland: ICH.